Dr. Jung has received a research grant from the Ministry of Science, ICT and Future Planning in Korea, entitled “Smart psychology analysis and healing therapy algorithm”. Dr. Jung’s current research interests include development of innovative convergent analysis methods for biomedical data and artificial intelligence-based patient referral system for clinical trials.

Dr. Howard Lee welcomed Dr. Jung, saying “It is just a right time for CCADD to have Dr. Jung on board. With Dr. Jung’s broad experience and skill sets in computational biomedical science, CCADD’s research palette will have more colors to advance its mission.”

Two young future leaders (Left:Se Rin Lee, Right:Hyewon Hwang) will spend the next eight weeks (July-August, 2017) at CCADD through the summer internship program at the Graduate School of Convergence Science and Technology, Seoul National University. Se Rin goes to Seoul National University College of Engineering in association with the Department of Industrial Engineering. Hyewon Hwang is a fourth-year undergraduate student at the College of Liberal Studies, Seoul National University with a double major in statistics and anthropology. 

Se Rin is well-versed in computer programming including Java and Python. She is interested in pursuing a career in the pharmaceutical industry, which has prompted her to take a previous internship at Pfizer Korea, where she explored the possibility of big data mining to increase the success probability of clinical trials. On the other hand, Hyewon wants to study the utility of statistics in guiding decision makings in drug development. She also has an excellent command of English.

Dr. Howard Lee spoke at the Advanced Course for the MFDS Reviewers, sponsored by the Korea Human Resource Development Institute for Health and Welfare on April 27, 2017. This educational activity was to refresh the clinical and nonclinical reviewers at MFDS by giving them a chance to get introduced to new ideas and technologies in drug development, particularly for clinical trial design issues. Dr. Lee provided a thorough review in the design of early clinical drug development trials.